Literature DB >> 10171428

Alzheimer's disease: the burden of the illness in England.

A Gray1, P Fenn.   

Abstract

This paper reports the findings of a study that estimated the socioeconomic costs, both direct and indirect, of Alzheimer's Disease in England by using a 'burden of illness' framework. The burden of illness was calculated for all main areas of provision: hospital and residential care, general practice, day care, home care and informal care, including the calculations of costs by age-group and by service provider. The results show that the cost of this care amounted to around 1,039m pounds in 1990/91, establishing that spending associated with Alzheimer's Disease is a major area of care expenditure. Such burden of illness data should help those involved with health care decision-making, planning and priority setting, especially for health districts and social services establishing base plans for care in the community.

Entities:  

Mesh:

Year:  1993        PMID: 10171428

Source DB:  PubMed          Journal:  Health Trends        ISSN: 0017-9132


  21 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Formal consensus and consultation: a qualitative method for development of a guideline for dementia.

Authors:  H Trickey; I Harvey; G Wilcock; D Sharp
Journal:  Qual Health Care       Date:  1998-12

4.  The dilemma of new drugs. Are costs rising faster than effectiveness?

Authors:  J Mason; N Freemantle
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

Review 5.  The cost of Alzheimer's disease. Will drug treatment ease the burden?

Authors:  W Max
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

6.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Alzheimer's disease: a treatment in sight?

Authors:  S Lovestone; R Howard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 8.  Donezepil for dementia.

Authors:  A Shah; M C Royston
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

9.  Current approaches to identifying the severely mentally ill.

Authors:  M Slade; R Powell; G Strathdee
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-05       Impact factor: 4.328

10.  Data requirements in a model of the natural history of Alzheimer's disease.

Authors:  T J Chaussalet; W A Thompson
Journal:  Health Care Manag Sci       Date:  2001-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.